These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 20562880)

  • 1. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.
    Nochi T; Yuki Y; Takahashi H; Sawada S; Mejima M; Kohda T; Harada N; Kong IG; Sato A; Kataoka N; Tokuhara D; Kurokawa S; Takahashi Y; Tsukada H; Kozaki S; Akiyoshi K; Kiyono H
    Nat Mater; 2010 Jul; 9(7):572-8. PubMed ID: 20562880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates.
    Yuki Y; Harada N; Sawada SI; Uchida Y; Nakahashi-Ouchida R; Mori H; Yamanoue T; Machita T; Kanazawa M; Fukumoto D; Ohba H; Miyazaki T; Akiyoshi K; Fujihashi K; Kiyono H
    Vaccine; 2023 Jul; 41(34):4941-4949. PubMed ID: 37385890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques.
    Fukuyama Y; Yuki Y; Katakai Y; Harada N; Takahashi H; Takeda S; Mejima M; Joo S; Kurokawa S; Sawada S; Shibata H; Park EJ; Fujihashi K; Briles DE; Yasutomi Y; Tsukada H; Akiyoshi K; Kiyono H
    Mucosal Immunol; 2015 Sep; 8(5):1144-53. PubMed ID: 25669148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cationic pullulan nanogel as a safe and effective nasal vaccine delivery system for respiratory infectious diseases.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Hum Vaccin Immunother; 2018; 14(9):2189-2193. PubMed ID: 29624474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit.
    Isaka M; Yasuda Y; Kozuka S; Miura Y; Taniguchi T; Matano K; Goto N; Tochikubo K
    Vaccine; 1998 Oct; 16(17):1620-6. PubMed ID: 9713937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies.
    Yasuda Y; Isaka M; Taniguchi T; Zhao Y; Matano K; Matsui H; Morokuma K; Maeyama J; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Jun; 21(21-22):2954-63. PubMed ID: 12798639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a nanogel-based nasal vaccine as a novel antigen delivery system.
    Nakahashi-Ouchida R; Yuki Y; Kiyono H
    Expert Rev Vaccines; 2017 Dec; 16(12):1231-1240. PubMed ID: 29053938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid.
    Westerink MA; Smithson SL; Srivastava N; Blonder J; Coeshott C; Rosenthal GJ
    Vaccine; 2001 Dec; 20(5-6):711-23. PubMed ID: 11738734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
    Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
    Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nanogel-based trivalent PspA nasal vaccine protects macaques from intratracheal challenge with pneumococci.
    Nakahashi-Ouchida R; Uchida Y; Yuki Y; Katakai Y; Yamanoue T; Ogawa H; Munesue Y; Nakano N; Hanari K; Miyazaki T; Saito Y; Umemoto S; Sawada SI; Mukerji R; Briles DE; Yasutomi Y; Akiyoshi K; Kiyono H
    Vaccine; 2021 Jun; 39(25):3353-3364. PubMed ID: 34016473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanogel-based nasal vaccines for infectious and lifestyle-related diseases.
    Azegami T; Yuki Y; Nakahashi R; Itoh H; Kiyono H
    Mol Immunol; 2018 Jun; 98():19-24. PubMed ID: 29096936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
    Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
    Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of mucosal immune responses and protection of cattle against direct-contact challenge by intranasal delivery with foot-and-mouth disease virus antigen mediated by nanoparticles.
    Pan L; Zhang Z; Lv J; Zhou P; Hu W; Fang Y; Chen H; Liu X; Shao J; Zhao F; Ding Y; Lin T; Chang H; Zhang J; Zhang Y; Wang Y
    Int J Nanomedicine; 2014; 9():5603-18. PubMed ID: 25506214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.
    Saito S; Ainai A; Suzuki T; Harada N; Ami Y; Yuki Y; Takeyama H; Kiyono H; Tsukada H; Hasegawa H
    Vaccine; 2016 Feb; 34(9):1201-7. PubMed ID: 26802605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid-in-oil nanodispersions for intranasal vaccination: Enhancement of mucosal and systemic immune responses.
    Kong Q; Kitaoka M; Tahara Y; Wakabayashi R; Kamiya N; Goto M
    Int J Pharm; 2019 Dec; 572():118777. PubMed ID: 31678377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Kozuka S; Taniguchi T; Matano K; Maeyama J; Komiya T; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 1999 Nov; 18(7-8):743-51. PubMed ID: 10547435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal and sublingual delivery of inactivated polio vaccine.
    Kraan H; Soema P; Amorij JP; Kersten G
    Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.